1. Dose-Dependent Acute and Sustained Renal Effects of the Endothelin Receptor Antagonist Avosentan in Healthy Subjects
- Author
-
T Littke, T Hengelage, Michel Burnier, Bruno Vogt, Marc Maillard, J Smolander, and C Zweiacker
- Subjects
Adult ,Endothelin Receptor Antagonists ,Male ,medicine.medical_specialty ,Adolescent ,Pyridines ,Sodium ,chemistry.chemical_element ,Blood Pressure ,Kidney ,law.invention ,Electrolytes ,Young Adult ,Heart Rate ,law ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,Pharmacology ,Cross-Over Studies ,Clinical pharmacology ,Dose-Response Relationship, Drug ,Renal sodium reabsorption ,Endothelin receptor antagonist ,business.industry ,Body Weight ,Antagonist ,Pyrimidines ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Regional Blood Flow ,Area Under Curve ,Renal physiology ,Endothelin receptor ,business ,Glomerular Filtration Rate - Abstract
The endothelin receptor antagonist avosentan may cause fluid overload at doses of 25 and 50 mg, but the actual mechanisms of this effect are unclear. We conducted a placebo-controlled study in 23 healthy subjects to assess the renal effects of avosentan and the dose dependency of these effects. Oral avosentan was administered once daily for 8 days at doses of 0.5, 1.5, 5, and 50 mg. The drug induced a dose-dependent median increase in body weight, most pronounced at 50 mg (0.8 kg on day 8). Avosentan did not affect renal hemodynamics or plasma electrolytes. A dose-dependent median reduction in the fractional renal excretion of sodium was found (up to 8.7% at avosentan 50 mg); this reduction was paralleled by a dose-related increase in proximal sodium reabsorption. It is suggested that avosentan dose-dependently induces sodium retention by the kidney, mainly through proximal tubular effects. The potential clinical benefits of avosentan should therefore be investigated at doses of ≤ 5 mg. Clinical Pharmacology & Therapeutics (2009); 85, 6, 628–634 doi:10.1038/clpt.2009.15
- Published
- 2009
- Full Text
- View/download PDF